- Home
- CEV vs CNTX Comparison
CEV vs CNTX Comparison
Compare CEV & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CEV
- CNTX
- Stock Information
- Founded
- CEV 1999
- CNTX 2015
- Country
- CEV United States
- CNTX United States
- Employees
- CEV N/A
- CNTX N/A
- Industry
- CEV Finance/Investors Services
- CNTX Biotechnology: Pharmaceutical Preparations
- Sector
- CEV Finance
- CNTX Health Care
- Exchange
- CEV Nasdaq
- CNTX Nasdaq
- Market Cap
- CEV 69.7M
- CNTX 75.6M
- IPO Year
- CEV N/A
- CNTX 2021
- Fundamental
- Price
- CEV $10.01
- CNTX $0.85
- Analyst Decision
- CEV
- CNTX Strong Buy
- Analyst Count
- CEV 0
- CNTX 5
- Target Price
- CEV N/A
- CNTX $5.25
- AVG Volume (30 Days)
- CEV 19.6K
- CNTX 121.2K
- Earning Date
- CEV 01-01-0001
- CNTX 11-05-2025
- Dividend Yield
- CEV 4.23%
- CNTX N/A
- EPS Growth
- CEV N/A
- CNTX N/A
- EPS
- CEV 0.36
- CNTX N/A
- Revenue
- CEV N/A
- CNTX N/A
- Revenue This Year
- CEV N/A
- CNTX N/A
- Revenue Next Year
- CEV N/A
- CNTX N/A
- P/E Ratio
- CEV $29.36
- CNTX N/A
- Revenue Growth
- CEV N/A
- CNTX N/A
- 52 Week Low
- CEV $8.83
- CNTX $0.49
- 52 Week High
- CEV $10.91
- CNTX $2.59
- Technical
- Relative Strength Index (RSI)
- CEV 77.83
- CNTX 55.84
- Support Level
- CEV $9.89
- CNTX $0.81
- Resistance Level
- CEV $10.01
- CNTX $0.87
- Average True Range (ATR)
- CEV 0.07
- CNTX 0.05
- MACD
- CEV 0.05
- CNTX -0.01
- Stochastic Oscillator
- CEV 88.89
- CNTX 39.79
About CEV Eaton Vance California Municipal Income Trust Shares of Beneficial Interest
Eaton Vance CA Muni Income Trust is a non-diversified closed-end investment company. The company's investment objective is to provide current income exempt from regular federal income tax and California state personal income taxes. It invests in municipal obligations, issued by the State of California or its political subdivisions, agencies, authorities and instrumentalities and also has some exposure to corporate bonds.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.